Value & Dossier advises Pharmaceutical and Biotechnology Companies in the AMNOG Process and in all matters of Market Access and Reimbursement.
Strategic dossier development with medical writing and statistical expertise for AMNOG and EU HTA
Tailored strategies for your product with our HTA expertise, gap and market analyses, our reference price calculator and more
Our experienced team supports pharmaceutical companies in bringing new products to market – whether through the German or the European procedure. From strategic planning and dossier preparation to successful price negotiations, we guide you safely through the entire health technology assessment process. We offer customized, business-specific solutions that highlight the value of your product and translate it effectively into benefit dossiers. Our expertise covers all aspects of the market access process, including reimbursement support and topics such as reference pricing, rebate contracts, and market analyses.
After more than 25 years of experience in market access, we are still fascinated by the unique strategic and substantive challenges that each individual project brings. Our clients’ success is what drives us and fuels our ambition. We approach every project with passion and provide high-quality analyses and customized solutions that best serve our clients’ interests.
After the implementation of the BStabG with far-reaching consequences, a reform of the AMNOG process itself (AMNOG 2.0) is now being discussed. Beyond that the Finance Committee on Health recently proposed expanding the role of cost-benefit assessments for reimbursement price negotiations, effective…
With the German Health Insurance Contribution Rate Stability Act (BStabG) now in force, statutory health insurances can establish cross-molecule rebate contracts for clusters of innovative, patent-protected medicines under §130e SGB For manufacturers, the implications are significant: Intensi…
The draft bill for the health care reform in Germany not only extends the price moratorium until 2030 but also cuts free pricing for nex Gx products. In the future, Gx prices for new products will depend on the existing market prices. The decisive factor will be whether a drug with the same active i…
The dynamic manufacturer rebate is a regulatory misstep The planned introduction of a dynamic manufacturer rebate for patent-protected medicines (§ 130a para. 1b SGB V) as part of the BStabG (statutory health insurance contribution rate stabilization bill) raises significant regulatory questions — p…
